Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Guizhou Yibai Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
SHSE:600594'
s EV-to-FCF Range Over the Past 10 Years
Min: -550.38 Med: 26.14 Max: 658.55
Current: 11.24
During the past 13 years, the highest EV-to-FCF of Guizhou Yibai Pharmaceutical Co was 658.55. The lowest was -550.38. And the median was 26.14.
SHSE:600594's EV-to-FCF is ranked better than 74.65% of 568
companies
in the Drug Manufacturers industry
Industry Median: 21.015
vs SHSE:600594: 11.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guizhou Yibai Pharmaceutical Co (SHSE:600594) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Guizhou Yibai Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Guizhou Yibai Pharmaceutical Co's share price for today is ¥3.30.
Guizhou Yibai Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.446.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Guizhou Yibai Pharmaceutical Co EV-to-FCF Related Terms
Guizhou Yibai Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Guizhou Yibai Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guizhou Yibai Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Guizhou Yibai Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Guizhou Yibai Pharmaceutical Co's EV-to-FCF falls into.
Guizhou Yibai Pharmaceutical Co's current Enterprise Value is ¥3,093 Mil.
Guizhou Yibai Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥258 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guizhou Yibai Pharmaceutical Co (SHSE:600594) has a EV-to-FCF of 11.97 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guizhou Yibai Pharmaceutical Co and its competitors. This is 54% below median its historical median of 26.14. According to the industry distribution chart, Guizhou Yibai Pharmaceutical Co ranks #144 out of 568 companies in the Drug Manufacturers industry, placing it in the top 25.4%.
Is Guizhou Yibai Pharmaceutical Co's EV-to-FCF too high?
Guizhou Yibai Pharmaceutical Co's current EV-to-FCF of 11.97 is 54% below median its 10-year median of 26.14. The Drug Manufacturers industry median EV-to-FCF is 21.02. Guizhou Yibai Pharmaceutical Co's value of 11.97 is 43% below this industry median. Based on the distribution chart, Guizhou Yibai Pharmaceutical Co ranks #144 out of 568 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Guizhou Yibai Pharmaceutical Co has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Guizhou Yibai Pharmaceutical Co's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Guizhou Yibai Pharmaceutical Co ranks #144 out of 568 companies for EV-to-FCF. This puts Guizhou Yibai Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 21.02. Guizhou Yibai Pharmaceutical Co's value of 11.97 is 43% below this benchmark. While the company's 10-year median is 26.14 vs. the industry median of 21.02, Guizhou Yibai Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.02, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guizhou Yibai Pharmaceutical Co's current EV-to-FCF of 11.97 is 43% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Guizhou Yibai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guizhou Yibai Pharmaceutical Co's current EV-to-FCF is 11.97, which is 54% below median its own 10-year median of 26.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhou Yibai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhou Yibai Pharmaceutical Co (SHSE:600594) is currently considered Fairly Valued. The stock's GF Value™ is ¥3.17, compared to a current price of ¥3.30 — trading 4.1% above its estimated fair value. The current EV-to-FCF is 11.97, which is 54% below median its 10-year median of 26.14 and 43% below the Drug Manufacturers industry median of 21.02. Guizhou Yibai Pharmaceutical Co's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Guizhou Yibai Pharmaceutical Co (SHSE:600594), the current EV-to-FCF is 11.97 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guizhou Yibai Pharmaceutical Co (SHSE:600594) Overvalued in 2026?
Based on GuruFocus' analysis, Guizhou Yibai Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥3.30 is trading 4.1% above its estimated GF Value™ of ¥3.17.
GuruFocus considers Guizhou Yibai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600594:
EV-to-FCF: 11.97 (54% below median its 10-year median of 26.14)
GF Value™: ¥3.17 vs. price of ¥3.30 (4.1% above fair value)
Industry Position: 43% below the Drug Manufacturers median (#144 of 568)
No single metric tells the full story. See the SHSE:600594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guizhou Yibai Pharmaceutical Co Business Description
Guizhou Yibai Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical products in China. Its products include tumor, cardio-cerebral vascular, respiratory system, anti-rheumatic, digestive system, pediatric, gynecological, andrological, anti-infection, anti-inflammatory, analgesic, tonic, and other drugs.
53GF Score
Get the complete analysis for SHSE:600594
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600594 has been successfully added to your 
